Daniel E. Everitt - Concepedia

Author

Daniel E. Everitt

Also Known As

D E Everitt, D EVERITT, D. E. Everitt, D. Everitt, D.E. Everitt, DANIEL E. EVERITT, Daniel E Everitt, Daniel E. Everitt, Daniel Everitt

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

TB Alliance Stellenbosch University Harvard University Task Applied Science University of Cape Town

About

Daniel E. Everitt is an author at TB Alliance specializing in medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	1.8K
2	Health Sciences	6	6	387
3	Nursing	4	4	325
4	Public Health	1	1	188
5	Social Sciences	1	1	90

Daniel E. Everitt

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis Francesca Conradie, Andreas H. Diacon, Nosipho Ngubane, New England Journal of Medicine	2020	962
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Francesca Conradie, Tatevik R. Bagdasaryan, Pauline Howell, New England Journal of Medicine	2022	507
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, The Lancet AntibioticsMedicineRandomised Trial14-Day Bactericidal ActivityAntibacterial Agent	2012	428
A Randomized Trial of a Program to Reduce the Use of Psychoactive Drugs in Nursing Homes Jerry Avorn, Stephen B. Soumerai, Daniel E. Everitt, New England Journal of Medicine	1992	397
A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis Catharine Lisa Kauffman, Nancy Aria, Eiko Toichi, Journal of Investigative Dermatology Clinical ImmunologyMedicineImmunologyInflammatory MarkerPlaque Psoriasis	2004	275
Treatment for glaucoma: adherence by the elderly. Jerry H. Gurwitz, Robert J. Glynn, Mark Monane, American Journal of Public Health	1993	267
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, The Lancet Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosis	2015	248
An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis Eiko Toichi, Gisela Torres, Thomas S. McCormick, The Journal of Immunology	2006	226
Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, American Journal of Respiratory and Critical Care Medicine	2015	200
Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis Honghui Zhou, Haishan Jang, Roy Fleischmann, The Journal of Clinical Pharmacology InflammationRheumatologyRheumatoid DisorderAutoimmune DiseasePharmacokinetic Modeling	2007	191

Page 1